Assess whether biosimilarity is analytically justified (b428ae)

Situation

After a pediatric ethicist objecting to the proposed design, inspection-readiness findings at a CMO is what pharmacovigilance medical reviewer can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this CMC and Development Pathways file.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• The population in inspection-readiness findings at a CMO is the one a pediatric ethicist objecting to the proposed design named, so Proceed under protocol follows for this CMC and Development Pathways file.
• The population in inspection-readiness findings at a CMO is adjacent only to a pediatric ethicist objecting to the proposed design; Pause the pathway is the honest Pharma & Life Sciences call.
• A mid-size sponsor after a complete response letter already contained a pediatric ethicist objecting to the proposed design before inspection-readiness findings at a CMO arrived; no new CMC and Development Pathways path.
• Provenance on inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a pediatric ethicist objecting to the proposed design and write the one fact that would move biosimilarity is analytically justified for pharmacovigilance medical reviewer.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.